BDRX VS BACK Stock Comparison

Performance

BDRX
10/100

BDRX returned -98.01% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

BACK
10/100

BACK returned -85.35% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

Volatility

BDRX
71/100

BDRX has had a higher than average amount of volatility over the last 12 months giving it a score of 71 of 100.

BACK
47/100

BACK has had a lower than average amount of volatility over the last 12 months giving it a score of 46 of 100.

Technicals

BDRX

"Technicals" not found for BDRX

BACK
43/100

BACK receives a 42 of 100 based on 14 indicators. 5 are bullish, 7 are bearish.

Earnings

BDRX

"Earnings" not found for BDRX

BACK
10/100

BACK has missed earnings 8 times in the last 20 quarters.

Profit

BDRX

"Profit" not found for BDRX

BACK
10/100

Out of the last 20 quarters, BACK has had 0 profitable quarters and has increased their profits year over year on 0 of them.

All score calculations are broken down here to help you make more informed investing decisions

Biodexa Pharmaceuticals plc American Depositary Shs Summary

Nasdaq / BDRX

Healthcare

Biotechnology

Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

IMAC Holdings, Inc. Common Stock Summary

Nasdaq / BACK

Healthcare

Medical - Care Facilities

IMAC Holdings, Inc. owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides physical therapy and spinal decompression, and chiropractic manipulation. The company owns or manages 15 outpatient medical clinics in Kentucky, Missouri, Tennessee, Illinois, Louisiana, and Florida. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Brentwood, Tennessee.

Power up your portfolio